Cardiovascular RiskESC-CVRISK2025NCT07613229
Evaluation of Cardiovascular Risks Among the Participants of the ESC Congress 2025
An observational study of Cardiovascular Risk, run by European Society of Cardiology at 1 site in Spain.
Trial summary
The European Society of Cardiology (ESC) is dedicated to promoting cardiovascular (CV) health and minimizing the occurrence of cardiovascular diseases throughout Europe. As a founding member of the European Alliance for Cardiovascular Health (EACH), the ESC is advocating for European and National Cardiovascular Health… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Cardiovascular Risk
- What is being tested?
- Questionnaire and Physical Exam, blood draw and auscultation
- Type of treatment
- Surgery or procedure, Lifestyle or therapy programme
- How many people
- 1,366 participants
- Where
- 1 siteSpain
- Study dates
- 29 Aug 2025to 1 Sep 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: All adult attendees (including healthcare professional) attending the ESC Congress 2026 from August 29th to September 1st
Who may be able to join
- All healthcare professionals (doctors, nurses, etc.) attending the ESC Congress 2025 from August 29th to September 1st
- Subjects who declare that they are able to understand and give IC in English
Who cannot join
- Subjects not willing to provide his/her consent to participate in the study.
- Subjects who are not suitable candidates for blood extraction.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Cross-Sectional Assessment of Cardiovascular Risk Among ESC Congress 2025 Participants
The European Society of Cardiology (ESC) is dedicated to promoting cardiovascular (CV) health and minimizing the occurrence of cardiovascular diseases throughout Europe. As a founding member of the European Alliance for Cardiovascular Health (EACH), the ESC is advocating for European and National Cardiovascular Health Plans which would include a cardiovascular and diabetes health check as part of a screening process for citizens. In line with this call for public health diagnosis of CV health, the ESC is committed to raising awareness on the need for actions and proposes to offer complimentary tests to delegates at ESC Congress 2025 in Madrid.
- Conditions
- Cardiovascular Risk
- Being tested
- Questionnaire and Physical Exam, blood draw, auscultation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Questionnaire and Physical ExamBehavioural
Questionnaire about demographics information, medical history and current CV medication.
blood drawBiological
Blood draw
Questionnaire and Physical ExamBehavioural
Blood pressure
auscultationProcedure or surgery
Auscultation procedure to measure the presence or absence of cardiac murmur and normal or abnormal heart sounds
What is being measured
The primary outcome is the main question the study is designed to answer.
Systemic Coronary Risk Evaluation 2 (SCORE2) algorithm in patients without established CVD (primary prevention).
Measured: At baseline
Second Manifestations or Arterial Disease (SMART) algorithm in patients with established CVD (secondary prevention)
Measured: At baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 May 2026
- Study start29 Aug 2025
- Primary completion1 Sep 2025
- Study completion1 Sep 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Cardiovascular RiskStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,366 participants (actual)
Sponsor and investigators
- Lead sponsor
- European Society of Cardiology
- Sponsor type
- Research network
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07613229
- Sponsor's protocol ID
- ESC-CVRISK2025
- Acronym
- ESC-CVRISK2025
- Status last verified
- May 2026
- First submitted
- 19 May 2026
- Last updated
- 29 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Wenzl FA, Wang Y, Mass V, Staeger FF, Siedlinski M, Satish M, Linde C, Bundgaard H, Fuster V, Guzik TJ, Ibanez B, Luscher TF; European Society of Cardiology and the REACT initiative. Cardiovascular Prevention among Healthcare Professionals: the ESC Congress Cardiovascular Health Check 2025. Eur Heart J. 2026 Aug 30:ehag736. doi: 10.1093/eurheartj/ehag736. Online ahead of print.
PubMed 42669131
Study at a glance
From the registry record, last updated by the sponsor on 29 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cross-Sectional Assessment of Cardiovascular Risk Among ESC Congress 2025 Participants
- ClinicalTrials.gov ID
- NCT07613229
- Acronym / sponsor ID
- ESC-CVRISK2025 / ESC-CVRISK2025
- Conditions
- Cardiovascular Risk
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,366 participants (actual)
- Lead sponsor
- European Society of CardiologyResearch network
- Study start
- 29 Aug 2025 (actual)
- Primary completion
- 1 Sep 2025 (actual)
- Study completion
- 1 Sep 2025 (actual)
- First posted
- 29 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The European Society of Cardiology (ESC) is dedicated to promoting cardiovascular (CV) health and minimizing the occurrence of cardiovascular diseases throughout Europe. As a founding member of the European Alliance for Cardiovascular Health (EACH), the ESC is advocating for European and National Cardiovascular Health Plans which would include a cardiovascular and diabetes health check as part of a screening process for citizens. In line with this call for public health diagnosis of CV health, the ESC is committed to raising awareness on the need for actions and proposes to offer complimentary tests to delegates at ESC Congress 2025 in Madrid.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- All adult attendees (including healthcare professional) attending the ESC Congress 2026 from August 29th to September 1st
Key inclusion criteria (2 listed)
- All healthcare professionals (doctors, nurses, etc.) attending the ESC Congress 2025 from August 29th to September 1st
- Subjects who declare that they are able to understand and give IC in English
Key exclusion criteria (2 listed)
- Subjects not willing to provide his/her consent to participate in the study.
- Subjects who are not suitable candidates for blood extraction.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Questionnaire and Physical ExamQuestionnaire about demographics information, medical history and current CV medication. | Behavioural | – |
| blood drawBlood draw | Biological | – |
| Questionnaire and Physical ExamBlood pressure | Behavioural | – |
| auscultationAuscultation procedure to measure the presence or absence of cardiac murmur and normal or abnormal heart sounds | Procedure or surgery | – |
Primary outcome
Systemic Coronary Risk Evaluation 2 (SCORE2) algorithm in patients without established CVD (primary prevention).
Time frame: At baseline
Second Manifestations or Arterial Disease (SMART) algorithm in patients with established CVD (secondary prevention)
Time frame: At baseline
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 May 2026.
- Derived from this study: PubMed 42669131Wenzl FA, Wang Y, Mass V, Staeger FF, Siedlinski M, Satish M, Linde C, Bundgaard H, Fuster V, Guzik TJ, Ibanez B, Luscher TF; European Society of Cardiology and the REACT initiative. Cardiovascular Prevention among Healthcare Professionals: the ESC Congress Cardiovascular Health Check 2025. Eur Heart J. 2026 Aug 30:ehag736. doi: 10.1093/eurheartj/ehag736. Online ahead of print.
Related trials for Cardiovascular Risk
RecruitingObservational study
AI-powered ECG Analysis Using Willem™ Software in High-risk Cardiac Patients (WILLEM)
Cardiomyopathies, Cardiac Arrest
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Recruiting
Decision Support for Chemoprevention
Breast Cancer
Active, not recruitingObservational study
Intravascular Lithotripsy in High Risk Calcified Iliac Anatomy for Transfemoral TAVR
Iliac Disease, Aortic Valve Stenosis
Not yet recruiting
Pilot Study Evaluating Catheter Directed Thrombolysis Device in Acute Intermediate Risk Pulmonary Embolism
Pulmonary Embolism (PE), Pulmonary Embolism With Right Ventricle Enlargement
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cardiovascular Risk, run by European Society of Cardiology at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Systemic Coronary Risk Evaluation 2 (SCORE2) algorithm in patients without established CVD (primary prevention). (time frame: At baseline). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07613229, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 May 2026.